Background-Morbidity and mortality after an acute myocardial infarction (AMI) has been reported to be higher in women than men. However, in some prior reports, women were not treated as aggressively as men, suggesting a treatment bias. We sought to determine whether sex influenced short-term outcomes in a cohort of AMI patients, all of whom underwent primary angioplasty. 
B
ecause cardiovascular disease is the leading cause of death among women in the United States, 1 it is of particular concern that the unadjusted in-hospital mortality after an acute myocardial infarction (AMI) is significantly higher among women compared with men. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The higher mortality in women may be partially explained by their increased age and the presence of more unfavorable prognostic factors. After adjustment for these factors, some, but not all, studies continue to show a survival disadvantage for women. 3, [15] [16] [17] [18] [19] [20] One potential explanation for the persistence of the mortality increase after risk adjustment is the finding that women frequently receive less aggressive treatment for AMI than do men. 18, 19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Specifically, women are less likely than men to undergo diagnostic catheterization, despite the fact that failure to perform catheterization has been associated with increased short-term mortality after AMI. 30, 31 Another possible explanation is the existence of fundamental biological differences between the response of men and women to myocardial infarction. We sought to assess the independent influence of sex on in-hospital outcome among patients uniformly treated with primary percutaneous transluminal coronary angioplasty (PTCA) for a first AMI. Other investigators have used the New York State Coronary Angioplasty database for studies of angioplasty treatment of AMI, 32 but sex differences in outcome have not been evaluated. This data set was used because it represents the experience across an entire state and includes patients treated in rural and urban, teaching and nonteaching, not-for-profit and for-profit hospitals. Furthermore, the data are not dominated by one or several institutions with particular expertise in the treatment of patients with AMI. Finally, the patients are those encountered in actual practice rather than the lower risk patients frequently selected for enrollment in clinical trials.
Methods

Data Ascertainment
We used data from the 1995 Coronary Angioplasty Reporting System of the New York State Department of Health (DOH). This registry was developed in 1990 to track and record important information on every patient undergoing PTCA in New York State. The responsible physician, or a designee, completes a questionnaire after each intervention, which is subsequently entered into a computer database and sent to the DOH. The questionnaire contains information on the hospital and cardiologist, patient demographics, procedural information, risk factors, discharge status, vessels diseased, lesion location and morphology, presence of bypass grafts, pre-and post-procedural stenosis, and complications. The DOH is the coordinating center, and hospitals and their catheterization laboratories are responsible for the accurate documentation and transfer of data. The DOH conducts periodic site visits to check for the accuracy of data entry, and errors and discrepancies are brought to the attention of each laboratory to be rectified.
The 1995 New York State Coronary Angioplasty Registry includes Ͼ22 000 patients undergoing elective and emergent PTCA in 32 hospitals. The time from symptom onset to treatment is recorded as Ͻ6 hours, 6 to 23 hours, or the number of days. Because significant numbers of patients with AMI present Ͼ6 hours from symptom onset 33 and late presentation may be associated with worse outcome, 34 we included patients who underwent attempted PTCA for AMI within 23 hours of symptom onset. This definition of primary PTCA is consistent with that used by the Society of Cardiac Angiography and Interventions. 35 We excluded patients with a prior AMI to examine the biological response to AMI in a population experiencing first AMI. We also excluded patients who had been treated with thrombolytic therapy within the previous 7 days or those with prior open-heart surgery. To determine the population from which the current study cohort was derived, we queried the New York State 1995 Statewide Planning and Research Cooperative System (SPARCS) database for all patients admitted to a hospital with a principal diagnosis of AMI (ICD-CM-9 code 410.xx).
Statistical Analysis
Categorical variables were compared by 2 analysis. Continuous variables are presented as meanϮSD and were compared using Student's t test. All probability values are 2-tailed. Statistical significance was defined as PϽ0.05 or CIs that did not include 1.0. Forward multiple logistic regression models were developed to identify predictors of in-hospital mortality. The model was constructed to determine the relation between sex and mortality among patients with AMI treated with PTCA. Variables sequentially added to the model included age, medical history, time to treatment, and hemodynamic status. The reference group consisted of male patients. Model discrimination was assessed by use of area under the receiver operating characteristic curve. A potential interaction between age and sex was examined using multivariate logistic regression, with age stratified at 75 years or with a linear age variable. All analyses were performed using the SPSS 8.0 statistical analysis program.
Missing Data
Baseline demographics, comorbidities, and procedure and outcome data were recorded in every case. However, ejection fraction values were missing for 30% of women and 33% of men. Logistic regression was performed both by excluding patients with missing values and by imputing an ejection fraction using the mean ejection fraction for each sex. The two models were equivalent.
Results
In New York state in 1995, 16 490 women and 22 705 men were admitted to one of 225 hospitals with a principal diagnosis of AMI. Primary angioplasty was performed in 32 hospitals on 1342 patients, of whom 410 (2.4% of female AMI patients in New York State) were women and 932 (4.1% of male AMI patients in New York State) were men. A total of 1044 patients, 317 women (1.9% of female AMI patients) and 727 men (3.2% of male AMI patients), treated in 32 hospitals with PTCA for first AMI were included in this analysis. Baseline characteristics of patients according to sex are presented in Table 1 . Women were older than men (65 versus 59 years, PϽ0.005) and were more likely to have hypertension (59% versus 44%, PϽ0.005), diabetes (19% versus 14%, Pϭ0.036), and peripheral or cerebrovascular disease (9.5% versus 5.5%, Pϭ0.019). Race, body mass index, and history of current smoking did not differ between sexes. Men were more often treated earlier than women (74% versus 63% treated within 6 hours of symptom onset, PϽ0.001).
Angiographic characteristics of patients are depicted in Table  2 . Left ventricular ejection fraction was not significantly different between women and men (47% versus 48%, PϭNS). The mortality rate for men with missing ejection fractions was 2.9%, compared with a mortality rate of 2.1% for men without missing values (Pϭ0.49). The mortality rate of women with missing ejection fractions was 10.4%, compared with a mortality of 6.8% for women without missing values (Pϭ0.27). There were no significant differences in number or distribution of diseased coronary vessels between women and men, including 3-vessel (12% versus 15%, PϭNS) and left main coronary disease (1.6% versus 0.7% PϭNS).
Procedural characteristics are shown in Table 3 . The annual PTCA experience of the treating physicians and hospitals did not differ between men and women. Before the procedure, significantly more women than men were either in shock (systolic blood pressure Ͻ80 mm Hg or cardiac index Ͻ2.0 L min -1 m -2 ) or required pharmacological or mechanical support to maintain blood pressure or cardiac output (25% versus 17%, Pϭ0.003). The use of balloon angioplasty, stent placement, and atherectomy was similar in women and men. A successful angioplasty result, defined by a reduction of treated vessel stenosis of at least 20% and a final diameter stenosis Ͻ50%, was achieved in 98% of women and 99% of men (PϭNS). Procedural complications, including stroke, abrupt closure, renal failure requiring dialysis, vascular complications, and emergency coronary bypass surgery were low and not significantly different between women and men.
The unadjusted in-hospital mortality rate was 7.9% in women and 2.3% in men (PϽ0.005; Table 4 ). The unadjusted odds ratio for death for women compared with men was 3.58 (95% CI, 1.9 to 6.7). Of note, the mortality of those Ͻ75 years of age was 1.6% among men and 5.5% among women (Pϭ0.001). The mortality of women Ն75 years of age was 14.6%, compared with 8.4% among older men (Pϭ0.212). Multivariate logistic regression analysis using either age of 75 as a discrete cut point or age as a linear variable did not reveal a significant age-sex interaction. Women who presented for treatment Ͻ6 hours after symptom onset had a mortality of 8.5% compared with 2.4% among men who were treated early (PϽ0.001). Treatment from 6 to 23 hours after symptom onset resulted in a mortality rate of 6.8% among women and 2.1% for men (Pϭ0.037). Within each sex, there was no significant difference in mortality between patients treated early or late.
After adjusting for baseline characteristics, including age, hypertension, diabetes, peripheral vascular or carotid disease, shock or hemodynamic instability, and time to treatment by multivariable logistic regression analysis, the odds ratio for in-hospital death for women remained significantly elevated at 2.33 (95% CI, 1.2 to 4.6, Pϭ0.016). For the final model, the area under the receiver operating characteristic curve was 0.87, which is consistent with excellent model discrimination ( Table 4) .
Discussion
The present study confirmed the plethora of previous studies that have demonstrated an increase in in-hospital mortality of women compared with men presenting with AMI. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] As in some, but not all, prior studies, 3,15-20 the increased risk of mortality persisted after correction for age and other medical conditions. The persistence of a survival disadvantage after risk-adjustment in prior studies may have been due to a lower rate of use of established treatments, such as aspirin, 19 ␤-blockers, 17, 19 thrombolytic treatment, 18 cardiac catheterization, 18, 30, 36 PTCA, 30 and bypass surgery 30 in women. A strength of the current study is its uniform application of primary angioplasty to all patients, thereby eliminating possible mortality differences caused by less aggressive treatment of women. Thus, the unique finding of the current study is that after adjusting for age, medical conditions, time to treatment, and hemodynamic status in patients uniformly 
Role of Age
A recent analysis of the Cooperative Cardiovascular Project data demonstrated a 24% increase in the risk of 30-day mortality among women compared with men presenting with AMI. 36 However, after adjustment for confounders such as age, preexisting conditions, illness severity, and treatment differences, no mortality difference remained. Of note, in this study, which was comprised exclusively of Medicare recipients, the mean age for women and men was 78.0 and 75.2 years, respectively. Other studies of elderly patients have also tended not to find sex-based differences in mortality. 2, 10, 37 However, studies that exclude elderly patients generally show higher mortality rates among women, even after adjustment for baseline differences, 7, 17, 38 suggesting an age-sex interaction. A recent analysis of the National Registry of Myocardial Infarction 2 data set found that the excess risk of mortality for women was accentuated at earlier ages and tended to disappear in older patients. 39 Although data from the current study show similar trends, the number of patients may not have been adequate to demonstrate a statistically significant agesex interaction.
Time to Treatment
Women with AMI generally present to the hospital later than men. 33 A longer time from symptom onset to presentation to the hospital has been associated with greater mortality in trials of thrombolytic therapy. 34 It remains undetermined whether late treatment increases mortality among patients treated with primary angioplasty. In the current study, later treatment did not increase mortality among women or men.
Response to Treatment
In contrast to studies of thrombolytic therapy for AMI in which women seem to experience reocclusion, hemorrhagic complications, and strokes more often than their male counterparts, 40 in this primary angioplasty study, the procedural success and complication rates were equal for men and women. Thus, rather than a differential response to treatment, our findings suggest that fundamental differences exist between the biology and pathophysiology of AMI among relatively younger men and women.
Biology
Estrogen seems to protect women against the development of coronary atherosclerosis. 41 Thus, when relatively young women develop an AMI after the rupture of vulnerable plaque, they have less severe coronary stenoses than older women or men. 42 Because of the relative paucity of advanced coronary stenoses before their infarction, women may not have previously generated an ischemic response capable of protecting the myocardium during infarction by triggering preconditioning 43 and/or the development of collateral blood supply. 44 Sex-related differences in myocardial physiology and compliance may also contribute tot he higher mortality among women. This study and others 20, 39, 40, 45 have observed that despite similar left ventricular systolic function, women have a higher prevalence of shock and hypotension after AMI than men. Whether more severe diastolic dysfunction accounts for the hemodynamic instability is not known. Other possible mechanisms for the worse outcome among women include sex-related differences in autonomic function after ischemia. Women have been shown to have an accentuated vagal response, with more frequent bradycardia and hypotension in the setting of ischemia compared with men. 46 
Implications
Until sex-specific treatments are developed to narrow the mortality difference between men and women, educational resources should applied to reinforce the role of primary prevention 47 and stress the earlier recognition of the frequently atypical symptoms of ischemia and infarction in women. Given the greater prevalence of adverse clinical characteristics and the associated increase in mortality among women, women should perhaps be referred more frequently rather than less often than men for aggressive, invasive therapy.
Limitations
Several important limitations need to be borne in mind when interpreting this study. First, because of its nonrandomized, retrospective nature, there may remain significant unrecognized differences between men and women, even after correction for the observed differences. However, unlike randomized trials, the current study included high-risk patients typically excluded from clinical trials, including those with advanced age and shock. Second, this data set does not include information on the treatment of patients with aspirin, ␤-blockers and ACE inhibitors, all of which have been shown to reduce mortality in the setting of AMI. It is possible that the undertreatment of women with these agents contributed to their increased mortality. Third, only in-hospital outcomes are analyzed in the current study. Although it is possible that the survival advantage for men would dissipate with extended follow-up, most deaths after AMI occur in the hospital. 48 Fourth, significant selection biases for primary angioplasty treatment exist for both men and women. It is possible that more women than men with high-risk characteristics not included in the database are referred for primary angioplasty. Finally, it is possible that women have a worse outcome in the hospital because they survive to be admitted to the hospital, whereas the sicker men die before they arrive at the hospital. The data in this area are unclear 48 and worthy of further investigation.
Conclusion
The persistence of a survival disadvantage for women undergoing the same aggressive treatment as men after adjustment for age, other comorbid conditions, time to treatment, and hemodynamic status suggests the possibility of basic biological differences in the response to AMI between men and women.
